Neuren Pharmaceuticals is a company that develops therapies for debilitating neurodevelopmental disorders that are characterised by impaired connections and signalling between brain cells. It provides trofinetide (NNZ-2566) and NNZ-2591, synthetic analogs of molecules that are derived from IGF-1 and occur naturally in the brain. The company develops medications to address Rett, Fragile X, Angelman, Phelan-McDermid, and other types of syndromes.